^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lung Non-Squamous Non-Small Cell Cancer

    Related cancers:
    20h
    Genomic landscape of stage 0-IA lung adenocarcinoma identified by on-site reflex targeted NGS. (PubMed, Lung Cancer)
    Reflex NGS at diagnosis in resected Stage 0-IA LUAD is feasible, rapid, and reveals a high rate of actionable alterations, which may support its integration in the future into early-stage diagnostic workflows.
    Retrospective data • Journal • Next-generation sequencing
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    TP53 mutation • BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • MET exon 14 mutation • ALK fusion • RET rearrangement • KRAS G12
    3d
    IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=43, Recruiting, Shanghai Pulmonary Hospital, Shanghai, China
    New P2 trial
    3d
    Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=54, Recruiting, Shanghai Pulmonary Hospital, Shanghai, China
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • ALK rearrangement
    |
    PD-L1 IHC 22C3 pharmDx
    |
    carboplatin • Tyvyt (sintilimab) • albumin-bound paclitaxel
    4d
    STELLAR-002: Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=1314, Recruiting, Exelixis | Active, not recruiting --> Recruiting
    Enrollment open
    |
    FH (Fumarate Hydratase)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016) • zanzalintinib (XL092)
    4d
    Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=25, Terminated, University of Michigan Rogel Cancer Center | Trial completion date: Jun 2028 --> May 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2025 --> May 2025; Due to financial hardships suffered by the stakeholder
    Trial completion date • Trial termination • Trial primary completion date
    |
    Keytruda (pembrolizumab) • carboplatin • Rubraca (rucaparib) • pemetrexed
    4d
    Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC (clinicaltrials.gov)
    P2, N=46, Not yet recruiting, Massachusetts General Hospital
    New P2 trial • IO biomarker
    |
    ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • RET fusion • ALK fusion • ROS1 fusion
    |
    carboplatin • pemetrexed • Yidafan (ivonescimab)
    5d
    TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations. (PubMed, Front Oncol)
    TROPION-Lung10 (NCT06357533) is a phase 3, open-label, multicenter, randomized study evaluating the efficacy and safety of first-line Dato-DXd plus rilvegostomig versus standard-of-care pembrolizumab in patients with advanced/metastatic nonsquamous NSCLC with PD-L1 TC expression ≥50% and without AGAs. TROPION-Lung10 will assess first-line Dato-DXd plus rilvegostomig in patients with advanced/metastatic NSCLC with high PD-L1 expression and without AGAs. ClinicalTrials.gov, identifier NCT06357533.
    P3 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Keytruda (pembrolizumab) • Datroway (datopotamab deruxtecan-dlnk) • rilvegostomig (AZD2936)
    7d
    Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 (clinicaltrials.gov)
    P1, N=28, Recruiting, University of Rochester | Active, not recruiting --> Recruiting | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Nov 2025 --> Nov 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • albumin-bound paclitaxel • pemetrexed
    7d
    Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors (clinicaltrials.gov)
    P1/2, N=370, Recruiting, Revolution Medicines, Inc.
    New P1/2 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    KRAS mutation • NRAS mutation • RAS mutation • HRAS mutation
    |
    Erbitux (cetuximab) • cisplatin • carboplatin • pemetrexed • Yidafan (ivonescimab) • elironrasib (RMC-6291)
    7d
    ELPIS: Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases (clinicaltrials.gov)
    P2, N=27, Enrolling by invitation, Yonsei University | Not yet recruiting --> Enrolling by invitation | Trial completion date: Apr 2026 --> Dec 2026 | Trial primary completion date: Jan 2026 --> Dec 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 mutation • HER-2 expression • HER-2 exon 20 mutation
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    7d
    Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT) (clinicaltrials.gov)
    P2, N=206, Active, not recruiting, Fondazione Ricerca Traslazionale | Not yet recruiting --> Active, not recruiting | Trial completion date: Apr 2023 --> May 2027 | Trial primary completion date: May 2022 --> May 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    7d
    NeoLazer: Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=160, Recruiting, Yonsei University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    carboplatin • pemetrexed • Lazcluze (lazertinib)